OBJECTIVES: The study sought to describe the authors' experience with mitral transapical transcatheter valve-in-valve implantation (TVIV). BACKGROUND: Increasing numbers of mitral biological prostheses are being implanted in clinical practice. Transcatheter valve-in-valve implantation may be a lower risk alternative treatment for high-risk patients with mitral valve degeneration. METHODS: Twenty-three consecutive patients with severe mitral bioprosthetic valve dysfunction underwent transapical mitral TVIV between July 2007 and September 2012. Bioprosthetic failure was secondary to stenosis in 6 (26.1%), regurgitation in 9 (39.1%), and combined in 8 (34.8%) patients. RESULTS: All patients were elderly (mean age 81 ± 6 years) and at high-risk for conventional redo surgery (Society of Thoracic Surgeons score 12.1 ± 6.8%). Successful transapical mitral TVIV was accomplished in all patients using balloon expandable valves (Edwards Lifesciences, Irvine, California) with no intraoperative major complications. One (4.4%) major stroke and 6 (26.1%) major bleeds were reported during hospitalization. Mitral transvalvular gradient significantly decreased from 11.1 ± 4.6 mm Hg to 6.9 ± 2.2 mm Hg following the procedure (p < 0.01). Intervalvular mitral regurgitation was absent (47.8%) or mild (52.2%) in all cases after mitral TVIV. No cases of transvalvular regurgitation were seen. All patients were alive on 30-day follow-up. At a median follow-up of 753 days (interquartile range: 376 to 1,119 days) survival was 90.4%. One patient underwent successful mitral TVIV reintervention at 2 months due to atrial migration of the transcatheter valve. All patients alive were in New York Heart Association functional class I/II with good prosthetic valve performance. CONCLUSIONS: Transcatheter transapical mitral valve-in-valve implantation for dysfunctional biological mitral prosthesis can be performed with minimal operative morbidity and mortality and favorable midterm clinical and hemodynamic outcomes.
OBJECTIVES: The study sought to describe the authors' experience with mitral transapical transcatheter valve-in-valve implantation (TVIV). BACKGROUND: Increasing numbers of mitral biological prostheses are being implanted in clinical practice. Transcatheter valve-in-valve implantation may be a lower risk alternative treatment for high-risk patients with mitral valve degeneration. METHODS: Twenty-three consecutive patients with severe mitral bioprosthetic valve dysfunction underwent transapical mitral TVIV between July 2007 and September 2012. Bioprosthetic failure was secondary to stenosis in 6 (26.1%), regurgitation in 9 (39.1%), and combined in 8 (34.8%) patients. RESULTS: All patients were elderly (mean age 81 ± 6 years) and at high-risk for conventional redo surgery (Society of Thoracic Surgeons score 12.1 ± 6.8%). Successful transapical mitral TVIV was accomplished in all patients using balloon expandable valves (Edwards Lifesciences, Irvine, California) with no intraoperative major complications. One (4.4%) major stroke and 6 (26.1%) major bleeds were reported during hospitalization. Mitral transvalvular gradient significantly decreased from 11.1 ± 4.6 mm Hg to 6.9 ± 2.2 mm Hg following the procedure (p < 0.01). Intervalvular mitral regurgitation was absent (47.8%) or mild (52.2%) in all cases after mitral TVIV. No cases of transvalvular regurgitation were seen. All patients were alive on 30-day follow-up. At a median follow-up of 753 days (interquartile range: 376 to 1,119 days) survival was 90.4%. One patient underwent successful mitral TVIV reintervention at 2 months due to atrial migration of the transcatheter valve. All patients alive were in New York Heart Association functional class I/II with good prosthetic valve performance. CONCLUSIONS: Transcatheter transapical mitral valve-in-valve implantation for dysfunctional biological mitral prosthesis can be performed with minimal operative morbidity and mortality and favorable midterm clinical and hemodynamic outcomes.
Authors: Jayendrakumar S Patel; Samir R Kapadia; Lourdes Prieto; E Murat Tuzcu; Amar Krishnaswamy Journal: Curr Treat Options Cardiovasc Med Date: 2015-11
Authors: Richard L Izzo; Ryan P O'Hara; Vijay Iyer; Rose Hansen; Karen M Meess; S V Setlur Nagesh; Stephen Rudin; Adnan H Siddiqui; Michael Springer; Ciprian N Ionita Journal: Proc SPIE Int Soc Opt Eng Date: 2016-04-05
Authors: T Thielsen; C Frerker; T Schmidt; M Schlüter; F Kreidel; H Alessandrini; K-H Kuck Journal: Internist (Berl) Date: 2016-04 Impact factor: 0.743
Authors: Navin Natarajan; Parag Patel; Thomas Bartel; Samir Kapadia; Jose Navia; William Stewart; E Murat Tuzcu; Paul Schoenhagen Journal: Cardiovasc Diagn Ther Date: 2016-04
Authors: Brian Whisenant; Samir R Kapadia; Mackram F Eleid; Susheel K Kodali; James M McCabe; Amar Krishnaswamy; Michael Morse; Richard W Smalling; Mark Reisman; Michael Mack; William W O'Neill; Vinayak N Bapat; Martin B Leon; Charanjit S Rihal; Raj R Makkar; Mayra Guerrero Journal: JAMA Cardiol Date: 2020-11-01 Impact factor: 14.676